CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...